As of 3:59pm ET
| +0.40 / +9.88%|
The 4 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 5.50, with a high estimate of 7.50 and a low estimate of 3.50. The median estimate represents a +23.60% increase from the last price of 4.45.
The current consensus among 5 polled investment analysts is to Hold stock in AcelRx Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.